Introduction
Cognitive impairment is an important non-motor symptom in Parkinson's disease (PD). A recent longitudinal study showed that 8.5% of PD patients with normal cognition developed this symptom in a year, reaching 47.4% in six year course of the disease [1] . Cognitive impairment is considered a predictor for dementia, which greatly affects functioning and quality of life [2] . Patients with PD have six-fold increased risk for developing dementia, comparing with healthy individuals [3] .
The pathophysiology of PD-related cognitive impairment and dementia is still unknown. It is believed that environmental and genetic factors contribute for the development of this symptom [3] . Among environmental factors, aging seems to be an essential contributor for cognition [4] . The role of dopaminergic deficiency as the main factor in cognitive dysfunction remains controversial. More recently, genes involved in neuroplasticity have been investigated in association with cognitive functions with interesting results.
Emerging evidence supports a role for brain-derived neurotrophic factor (BDNF) protein on cognition in normal and neuropathological conditions. BDNF is involved in neuroplasticity, it is highly expressed and widely distributed in the brain [5] . It promotes survival, differentiation and maintenance of neuronal cells. BDNF appears to be a mediator in long-term potentiation (LTP), which is involved with memory formation in the hippocampus [6] . In healthy elderly, BDNF levels in serum and urine were associated with cognitive functioning [7, 8] .
A functional polymorphism, Val66Met, seems to impair BDNF secretion in hippocampal mice cells [9] . The 66Met substitution in BDNF prodomain alters its interaction with molecules responsible for BDNF intracellular trafficking [10] . Val66Met has already been linked to smaller volumes of multiple brain regions and impaired episodic memory function [6] . Although Val66Met BDNF is not associated with PD susceptibility [11] , it has been associated with cognitive impairment [12] and planning ability in PD [13] . However, two studies did not find an association between this polymorphism and cognitive functioning in PD [14, 15] . In view of contradictory findings, the present study aim to determine if BDNF Val66Met was associated with cognitive impairment in PD, as measured by the Mini-Mental State Examination (MMSE) [16] .
Subjects and methods

Subjects
A total of 175 idiopathic PD patients with age at onset of motor symptoms after 45 years were included. Diagnostic processes and clinical evaluation were described elsewhere [17, 18] . Briefly, patients were diagnosed and recruited at the Movement Disorders clinics at "Hospital de Clínicas de Porto Alegre" in Brazil from 2006 to 2014. Diagnosis was based on UK Parkinson Disease Society Brain Bank criteria [19] . Patients with atypical manifestations, secondary parkinsonism or with familial history of the disease were excluded. Patients and their caregivers underwent a structured interview for clinical and demographic data collection. Information was also obtained from medical records. A trained physician applied the Unified Parkinson's Disease Rating Scale (UPDRS), Hoehn & Yahr and the Mini-Mental State Examination (MMSE) for global cognitive abilities. Parkinson's disease patients in our sample were not diagnosed for dementia, because the MMSE scale defines only cognitive impairment. Parkinson's disease patients with dementia are probably included in the group of impaired cognition but were not considered in this study as a different cohort. Hoehn & Yahr measures the motor staging or severity of PD from 1 to 5, being 5 the worst scenario. One patient was excluded from multivariate analysis because his/her Hoehn & Yahr data record was not available. The hospital Ethics Committee approved the study and all participants gave written informed consent to participate.
Genotyping
Peripheral blood samples were collected from all patients. DNA was extracted by standard procedures [20] . The Val66Met BDNF polymorphism (rs6265) was genotyped as previously described [21] .
Statistical analyses
Allele frequencies were estimated by gene counting. Agreement of genotype frequencies to Hardy-Weinberg expectations was tested using a goodness of fit 2 test.
The MMSE scale was analyzed as a continuous variable by Mann-Whitney and/or Kruskal-Wallis test because this scale does not have a normal distribution. Cognitive impairment was determined by cut-off scores according to the educational level validated in Brazil [22] . These cut-off scores were: 20 (illiterates); 25 (1-4 years of schooling); 26 (5-8 years of schooling); 28 (9-11 years of schooling) and 29 (12 or more years of schooling).
Clinical and demographic data between genotypes were assessed by univariate analyses using chi-square for categorical variables and, Mann-Whitney for continuous variables. BDNF Met carriers were grouped and compared to Val/Val homozygotes due to low frequency of Met/Met genotype. Non-parametric bivariate correlations were performed using Spearmans correlation coefficient. Multiple Poisson regression with robust variance estimators was used to assess the effect of polymorphisms on risk of cognitive impairment, because this outcome was very frequent. To determine potential confounders to be included in the multiple Poisson regression, a p < 0.1 in univariate analyses was established. MMSE was the dependent variable and gender, disease duration, European ancestry and Hoehn & Yahr were included as confounders. Education was not used as confounder, due to its previous use to classify MMSE scores according to education. Statistical significance was defined as a two-tailed p-value <0.05.
Results
BDNF Val/Val, Val/Met and Met/Met genotypes frequencies were 66.9%, 29.1%, and 4.0% respectively. The genotype distributions were in Hardy-Weinberg equilibrium. The BDNF Val66Met allele frequencies observed herein did not differ from those previously described in Brazilians [23, 24] .
Based on MMSE cut-offs about 53.7% of the patients presented cognitive impairment. Overall mean MMSE was 24.5 ± 4.0. Table 1 shows demographic and clinical variables for the whole sample and stratified by cognitive impairment. The mean age between those with and without cognitive impairment did not differ. Disease severity (as measured by Hoehn & Yahr) and disease duration were independent risk factors for cognitive impairment (p = 0.0001 and p = 0.044 respectively). Patients with cognitive impairment presented higher disease severity (2.8 ± 0.8 points) and higher disease duration (9.2 ± 5.7 years) compared to those without this symptom (2.4 ± 0.6 points and 7.4 ± 4.4 years, respectively).
Most BDNF 66Met allele carriers (65.5%) were males (p = 0.007), only 34.5% were females (Table 2) . BDNF 66Met carriers presented mean lower MMSE scores (1.9 points) when compared to Val/Val homozygous subjects (p = 0.005). Cognitive impairment was associated with presence of at least one Met allele (p = 0.036) in Multiple Poisson regression analyses were performed to estimate BDNF effects on cognitive impairment. The BDNF 66Met allele was associated with cognitive impairment in PD (p = 0.005 RR = 1.45 IC = 95% [1.1-1.8]) after controlling for gender, ancestry, disease duration, and disease severity (Table 3) . It was also shown that ancestry and disease severity were independent risk factors for cognitive impairment. The overall model adequacy was estimated by the likelihood ratio 2 test ( 2 = 13.22 p = 0.021).
Discussion
The major finding reported herein was the association of BDNF Val66Met polymorphism with cognitive impairment. BDNF Met carriers showed a higher frequency of cognitive impairment than Val/Val homozygotes and therefore, a lower MMSE score. This finding is supported by the evidence that this variant seems to modulate BDNF secretion in 18% (heterozygous) to 26% (homozygous) subjects [9] . The Met allele seems to decrease neuronal dendrites distribution and decrease targeting to secretory granules, lowering the extracellular BDNF levels [25] . Moreover, this finding is supported by a study that demonstrates that Val/Met heterozygotes form protein heterodimers that affect the protein trafficking fate [26] .
Four studies investigated the association between BDNF Val66Met and cognitive impairment of PD. In 2005, Foltynie et al. [13] recruited 291 patients to investigate the impact of BDNF Val66Met in the United Kingdom. The cognitive impairments of the patients were assessed using the MMSE, the pattern recognition and spatial recognition task. The main result of this investigation was the association of the BDNF polymorphism with planning ability in PD. Guerini et al. [12] reported an association between BDNF 66Met allele and higher risk of cognitive impairment in PD patients based on their MMSE score. This study enrolled 294 Italian patients with PD and 233 healthy controls. The present study is an independent demonstration that BDNF 66Met allele affects global cognition, and may be one of the genetic risk factors for the occurrence of cognitive impairment in PD patients. However, two studies from Serbia (n = 244) and Poland (n = 177) did not find an influence of BDNF genotypes on cognition [14, 15] . Although not strictly comparable, Bialecka et al. [14] did not observe an association of BDNF genotypes with PD's dementia. It is possible that BDNF Val66Met is associated with intellectual impairment per se and not with dementia that might have several different causes. These discrepancies might be due to different methodologies to assess cognitive impairment, even using MMSE. Different cut-offs might have been considered as cognitive impairment in different studies due to differences in years of schooling. Genotyping procedures also varied among studies which could have introduced some heterogeneity. Although all populations are of European ancestry, the genetic background might differ among them. Moreover, overlap of neurodegenerative diseases such as Alzheimer's disease and PD might also contribute to the conflicting results observed; clearly more studies are warranted to understand the role of BDNF variation on cognitive impairment.
In the present study, 53.7% of PD patients presented cognitive impairment. The proportion of cognitive impaired patients was high compared to Pigott et al. [1] longitudinal study. However, they measured six-year-course of the disease and our disease duration was higher, of medium duration of 8.4 years. Epidemiological studies disclosed that higher age, severity of motor symptoms, older age at onset, higher disease duration and male gender were likely to be risk factors of PD cognitive dysfunction [2, 27] . Besides BDNF Val66Met polymorphism, only disease severity and disease duration were associated with cognitive impairment in this study.
The results presented herein must be interpreted in the context of some limitations. First, the association observed might be attributed to other events, but our results remained significant even after controlling for important factors such as age, ancestry, and disease duration, suggesting that BDNF Val66Met is independently associated with cognitive impairment in PD. Second, intellectual impairment was assessed using the MMSE, which is a fairly crude measure and possibly not the best to detect PD-associated cognitive dysfunction. Since only the MMSE scale was employed, it was not possible to characterize dementia in these patients. However, the MMSE scale remains the most widely used test for cognitive screening, including PD patients. Therefore, it is important to highlight that our study concludes about marked cognitive impairment and not about Parkinson's disease dementia. A detailed evaluation of the impact of the cognitive dysfunction in daily living activities would be warranted to apply the criteria for Parkinson's disease dementia [28] .
In a recent revision, Halliday et al. [29] differentiated dementia and mild cognitive impairment in PD and suggested that different genetic factors could play a role in these two conditions. Nevertheless few genetic studies have been conducted with cognitive impairment in PD, and most have focused on the end point of dementia, our findings cannot definitively establish whether the association observed between BDNF and cognitive decline is specific to PD or simply the effect of BDNF genotype on cognitive function. Therefore, given the importance of cognitive impairment in PD and the apparent influence of genetic factors in this condition, Table 3 Poisson regression analysis of risk factor for cognitive impairment in Parkinson's disease. further prospective studies are clearly needed to elucidate the role of genetic factors on cognitive impairment in PD.
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